Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | +2.91% | +0.95% | +0.95% |
01/04 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
26/03 | Transcript : Quince Therapeutics, Inc. - Special Call |
Sales 2022 | - | Sales 2023 | - | Capitalization | 45.01M 3.75B |
---|---|---|---|---|---|
Net income 2022 | -51M -4.25B | Net income 2023 | -31M -2.58B | EV / Sales 2022 | - |
Net cash position 2022 | 89.73M 7.48B | Net cash position 2023 | 61.24M 5.11B | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.41
x | P/E ratio 2023 |
-1.25
x | Employees | 32 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.94% |
Latest transcript on Quince Therapeutics, Inc.
1 day | +2.91% | ||
1 week | +0.95% | ||
1 month | -6.19% | ||
3 months | -15.87% | ||
6 months | +9.27% | ||
Current year | +0.95% |
Managers | Title | Age | Since |
---|---|---|---|
Dirk Thye
CEO | Chief Executive Officer | 54 | 19/22/19 |
Brendan Hannah
DFI | Director of Finance/CFO | 39 | 01/22/01 |
Charles Ryan
PSD | President | 60 | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Una Ryan
BRD | Director/Board Member | 82 | 01/18/01 |
Luca Benatti
BRD | Director/Board Member | 63 | 23/23/23 |
Dirk Thye
CEO | Chief Executive Officer | 54 | 19/22/19 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1.06 | +2.91% | 120,833 |
25/24/25 | 1.03 | -2.83% | 93,060 |
24/24/24 | 1.06 | -4.50% | 91,171 |
23/24/23 | 1.11 | +4.72% | 129,361 |
22/24/22 | 1.06 | +0.95% | 57,652 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
+0.95% | 45.81M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- QNCX Stock